The Life Sciences team advised Legend Capital in the intellectual property due diligence of N1 Life Inc. in connection with its multi-million Pre-A round investment in N1 Life. The invested funds will be used for further screening and optimization of peptide and nano dual-platform technologies and the preclinical development of N1 Life’s first anti-tumor pipeline.
Legend Capital has been adhering to internationally accepted standards to create best practices in fund management and operation. With a proven track record of more than 20 years, it now has full experience in fund management and operation and has built an extensive partner ecosystem across the entire investment chain.
N1 Life, a bio-pharma company spun out from Stanford University and founded by Dr. Paul A. Wender, a world-renowned translational scientist and professor, and Dr. Xiaoyu Zang, an entrepreneurial scientist and rising-star in biopharmaceutical field, focuses on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human and companion animals.
The Goodwin team was led by Can Cui and included Yingying Cai.
Legend Capital has been adhering to internationally accepted standards to create best practices in fund management and operation. With a proven track record of more than 20 years, it now has full experience in fund management and operation and has built an extensive partner ecosystem across the entire investment chain.
N1 Life, a bio-pharma company spun out from Stanford University and founded by Dr. Paul A. Wender, a world-renowned translational scientist and professor, and Dr. Xiaoyu Zang, an entrepreneurial scientist and rising-star in biopharmaceutical field, focuses on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human and companion animals.
The Goodwin team was led by Can Cui and included Yingying Cai.